MGI (BGI Group)
MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment …
Profile
MGI Tech Co., Ltd. (MGI) is a publicly traded biotechnology company headquartered in Shenzhen, China, that develops and manufactures core tools for life sciences, including DNA sequencing instruments, laboratory automation, and multi-omics platforms. Founded in 2016, the company is listed on the Shanghai Stock Exchange (ticker: 688114).
MGI’s core technology includes its proprietary DNBSEQ sequencing and CycloneSEQ nanopore sequencing. Its product portfolio spans short-read and long-read sequencing, spatial transcriptomics, and automated lab systems. As of mid-2026, the company employs over 2,200 people and serves more than 3,500 users across six continents.
In 2025 and 2026, MGI expanded its “SEQ ALL” strategy, integrating generative AI into its workflows, such as the AI-powered G400RS FluoXpert Vision and E25 Flash sequencer. The company remains active, recently acquiring entities like STOmics and Huada Xufeng to bolster its integrated multi-omics ecosystem. MGI is led by CEO Jian Liu and Chairman Jian Wang, with major ownership held by Jian Wang.
Sources#
- 华大智造—创新智造引领生命科技
- MGI Tech Co., Ltd. (688114.SS) company profile and facts - Yahoo Finance
- MGI Tech 2026 Company Profile: Stock Performance & Earnings | PitchBook
- MGI Tech Celebrates 10 Years of DNBSEQ™ Technology: Driving Genomics Forward with Speed, Scale, and Accessibility — 2025-04-13
- Copyright Disclaimer: The copyright of this brochure is solely owned by MGI Tech Co., Ltd. The information included in this brochure or part of, including but not limited to interior design, cover design and icons, is strictly forbidden to be reproduced or transmitted in any form, by any means (e.g. electronic, photocopying, recording, translating or otherwise) without the prior written permission by MGI Tech Co., Ltd. All the trademarks or icons in the brochure are the intellectual property of MGI Tech Co., Ltd. and their respective producers. Version: January 2026 Information in this brochure is updated to [2026-01-27] and only for your reference. In no event shall the brochure be regarded as warranty or commitment made by MGI Tech Co., Ltd. All rights and obligations shall subject to final executed agreement. *Unless otherwise informed, this StandardMPS sequencing reagent is not available in Germany, UK, Sweden, and Switzerland.
- MGI Tech Celebrates 10 Years of Innovation, Empowering 3,560 Users Across Six Continents — 2026-04-13
- MGI has launched new gene sequencers, leading the trillion-dollar track of life sciences with dual “new” drives
- MGI Tech Co., Ltd.: Shareholders Board Members Managers and Company Profile | CNE100005PC8 | MarketScreener
- Industry
- Digital & robotics, Feed, Industrial chemistry
- Topics
- Gene synthesis, sequencing & bio-tools, Synthetic biology platforms & biomanufacturing, Animal feed & feed additives
- Role
- Producer — “…n, China, that develops and manufactures core tools for life sciences, including DNA sequencing instruments, l…”
Bio-solutions it supplies 0
Not yet cited as a supplier in a graded solution.
What they offer
This company does not publish its products or services — we find out through an introduction.
News & status 6
- 2026-02 and 2026-03 Latest status: MGI Tech announced the divestment of its US subsidiary Complete Genomics in February 2026 and the acquisition of STOmics and CycloneSEQ in March 2026. ↗ ↗ ↗
- 2026-04-10 MGI Tech Obtains China NMPA Approval for DNBSeq-T1+ Sequencer | GenomeWebMGI Tech (a subsidiary of the BGI Group) has obtained NMPA medical device registration for its DNBSeq-T1+ sequencer, enabling clinical deployment in China for cancer diagnostics, rare disease testing, and genetic screening. The T1+ is a benchtop platform that …
- 2026-02-02 MGI Tech to Acquire BGI's Spatial, Nanopore Sequencing Subsidiaries for RMB 365.7M in Cash | GenomeWebMGI Tech plans to acquire BGI Group subsidiaries STOmics (spatial sequencing) and CycloneSeq (nanopore sequencing) for RMB 365.7 million in cash, expanding its in-house capabilities and aiming to become a one-stop provider under its Seq All strategy. The deal, …
- 2026-02-24 China’s MGI Tech to Divest US Subsidiary Citing Geopolitics - BloombergMGI Tech (a unit of BGI Group) plans to divest its US subsidiary, Complete Genomics, citing a harsher policy environment, signaling a retreat from its decade-long US expansion. The sale to Swiss Rockets AG for about $50 million indicates strategic retrenchment …
- 2026-05-26 MGI Tech, BGI Affiliates Served UK Lawsuit by Oxford Nanopore for Contract Breach | GenomeWebMGI Tech and several BGI Group affiliates are facing a UK lawsuit from Oxford Nanopore for breach of contract, misuse of confidential information, and misappropriation of trade secrets related to the CycloneSeq WuTong02 technology, with Oxford Nanopore seeking …
- 2026-08-19 Caught in the Middle: Chinese Biotech Firms’ Divergent Responses to U.S. Sanctions | Carnegie Endowment for International PeaceBGI Group’s MGI Tech, having divested its U.S. unit in 2026 amid geopolitical tensions, signals a strategic retreat from Western markets and a pivot to Beijing-aligned growth in the Global South, reinforcing BGI’s close ties to the Chinese state while …
- 2026-08-28 Corporate Update-BGI Group Official Website- The page notes that BGI-Research and MGI jointly submitted a patent for spatial information detection enabling BGI’s Stereo-seq, highlighting collaboration between BGI Group and MGI in core technology development. - It also credits MGI in achieving a Gold …
Network: owners, partners, peers
Partners & deals 1
| counterparty | Swiss Rockets AG (acquirer of Complete Genomics) …MGI Tech announced the divestment of its US subsidiary Complete Genomics in February 2026 and the acquisition of STOmics and CycloneSEQ in March 2026.… |
Similar companies
Genomics BioSci & Tech Co Ltd · Takara Bio Inc. · Tsingke Biotech · 北京诺禾致源科技股份有限公司 · RiboBio · Shimadzu (Asia Pacific) · Yikon Genomics · ALLSHENG
Identity & contacts
Contacts, people and legal identity are available to members.
Sign in as a member